Alcoholism Clinical Trial
Official title:
The Effects of Quetiapine on Sleep During Alcohol Abstinence
The primary purpose of this study is to determine how efficacy of quetiapine (seroquel XR) in improving the sleep in recovering alcohol dependent subjects.
Sober alcohol dependent subjects frequently complain of difficulty falling asleep as well as
staying asleep which may eventually lead to relapse. Novel antipsychotic medications such as
quetiapine have shown some efficacy in treating alcoholism and have also shown some benefit
in improving insomnia.
The primary aim of this study is to determine the degree to which quetiapine improves sleep
in veterans during the early phase of recovery from alcohol dependence. The sleep efficiency
from an in-lab polysomnogram will be the primary outcome measure. Secondary measures of
sleep will include the Pittsburgh Sleep Quality Index, Insomnia Severity Index, and
actigraphy. Other additional aims will explore for alcohol use and cravings, change in
psychiatric symptoms using the The Time Line Follow Back measure, Penn Alcohol Craving Scale
(PACS), the Patient Health Questionnaire-9 item scale (PHQ-9), and the Beck's Anxiety
Inventory (BAI) respectively.
Twenty four subjects within the first year of sobriety will be enrolled. Participants will
be undergo an extensive baseline screening procedure. After 2 consecutive in-laboratory
polysomnograms they will be treated with either Quetiapine XR or matching placebo pills
targetting a dose of 400 mg a night. The treatment duration will be 8 weeks and during the
eight week of treatment they will undergo 2 more nights of in-laboratory polysomnogram. All
subjects will also receive Medical Management therapy, a standardized psychosocial
intervention which is medically-based and focusses on alcohol abstinence and medication
compliance.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05054738 -
CRP and S&A for Inpatient Veterans
|
N/A | |
Completed |
NCT02233738 -
Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services
|
N/A | |
Completed |
NCT05877807 -
Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
|
||
Completed |
NCT00000437 -
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
|
Phase 4 | |
Completed |
NCT00536146 -
The Stress-Hormone System in Alcohol-Dependent Subjects
|
N/A | |
Terminated |
NCT00890149 -
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
|
Phase 2 | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02939352 -
The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues
|
Early Phase 1 | |
Completed |
NCT01553136 -
Varenicline Treatment of Alcohol Dependence in Smokers
|
Phase 2 | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Completed |
NCT01389297 -
Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery
|
N/A | |
Completed |
NCT01760785 -
Valproate for Mood Swings and Alcohol Use Following Head Injury
|
N/A | |
Completed |
NCT00768508 -
Combined Pharmacotherapies for Alcoholism
|
Phase 3 | |
Completed |
NCT01113164 -
Matching Genotypes and Serotonergic Medications for Alcoholism
|
Phase 1 | |
Terminated |
NCT02842528 -
Cognitive Vulnerability Factors in Alcohol-dependence
|
N/A | |
Completed |
NCT00127231 -
Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women
|
N/A | |
Completed |
NCT00367575 -
An Internet-based Intervention for Problem Drinking
|
N/A | |
Completed |
NCT00223639 -
New Medications to Treat Alcohol Dependence
|
Phase 2 | |
Completed |
NCT00583440 -
12-step Facilitation for the Dually Diagnosed
|
Phase 1/Phase 2 | |
Completed |
NCT00167687 -
Prazosin Alcohol Dependence IVR Study
|
Phase 4 |